ÂÜÀòÂÒÂ×

Dr. Steve Wring is Altavant’s Senior Vice President of Research and Development, head of the translational medicine team, and project lead for ALTA-2530. Dr. Wring has over a 25-year track record of drug development in the UK and USA with a focus on nonclinical research. Before joining Roivant in 2016 and subsequently Altavant at its formation in 2018, Dr. Wring spent 15 years with Trimeris and Scynexis where he focused primarily on anti-infective research and development. In these roles, Dr. Wring worked on the optimization and development of synthetic peptide fusion inhibitors for HIV, a cyclophilin inhibitor for hepatitis C, multiple anti-parasitic products for neglected tropical diseases, and a first-in-class antifungal for treating invasive disease. Earlier in his career, he worked across portfolios in non-clinical research at GSK and Glaxo-legacy companies in the UK and USA.

Dr. Wring earned MSc and Ph.D. qualifications in chemistry at the University of the West of England, UK. His recent research interests and publications have focused on the use of pharmacokinetic and pharmacodynamic efficacy data in nonclinical disease models to select doses for clinical evaluation together with clinical pharmacology studies to support the development and regulatory submissions. Dr. Wring has extensive regulatory experience authoring and supporting nonclinical submissions to US, Canadian, EU, and Japanese agencies.